MGC Pharma submits patent application for CimetrA to European IP Office
LONDON: MGC Pharmaceuticals Ltd (ASX: MXC) announced the successful submission of a patent application for CimetrA to the Slovenian Intellectual Property Office (SIPO), assigned to MGC Pharma.
MGC Pharma submitted its patent application which was accepted by SIPO on 5 May 2021 which is the priority date for the patent, giving the Company priority to file subsequent patent applications for CimetrA in other jurisdictions and to other IP Agencies such as the EU and WIPO. MGC Pharma expects the patent to be issued within the next 12 months.
The patent provides a nano-micellular pharmaceutical synergetic composition consisting of Curcumin, Boswellia, Artemisinin, and optionally Cannabinoids and/or Nitroxides.
The composition can be manufactured in liquids or in solid pharmaceutically acceptable carriers, has antioxidant, anti- inflammatory, immuno-modulating, anti-viral and anti-cancer properties and can be designed for multiple therapeutic applications, utilising self-nanoemulsifying drug delivery systems (SNEDDS).
The patent sets out the specific antioxidant, anti-inflammatory, immune-modulating, anti-viral, and anti-cancer properties of CimetrA, designed for multiple therapeutic applications including the treatment of chronic inflammation, severe acute respiratory syndrome coronavirus (SARS-Covid, COVID-19) and heavy variants of influenza, as well as various types of cancer.
This is in addition to its efficacy in relation to the regulation of the human body’s circadian rhythm and homeostasis which promotes an immune response to bacterial, viral, fungal and parasitic infections. It’s wide range of uses as a treatment highlights its versatility as an IMP.
Preclinical and clinical results to date support the pharmaceutical composition of CimetrA as an effective treatment for addressing anti-inflammation and cytokine over-production (known as cytokine storm) in all tested COVID-19 patients.
Many plant molecules which make up the API are hydrophobic (not water soluble) and thus cannot be readily absorbed by the body. Once these are encapsulated within the oil-free type IV nano-micellar SNEDDS, the bioavailability of the molecules is increased and the API are emulsified and absorbed more efficiently, resulting in more effective treatment.
The submission of this patent therefore has significant implications for the pharmaceutical industry and will ultimately help to increase general drug efficiency.
MGC Pharma is advancing the clinical development program for CimetrATM as an IMP to demonstrate the full efficacy and pharmacokinetic profile of the treatment in relation to treating different variants of COVID-19, through a Phase III clinical trial that is expected to commence shortly (See 22 March 2021 announcement).
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “We are delighted that the SIPO recognises the unique formulation of CimetrA, something we believe will be transformational in the treatment of COVID 19 as well as numerous other conditions. The submission of this patent application is an important next step in bringing CimetrA to market in multiple jurisdictions and ultimately treating people and patients on a global scale whilst Phase III trials for the IMP continue”.
MGC Pharmaceuticals Ltd (ASX: MXC)
Share price
0.053 AUD −0.0030 (5.36%)
17 May, 4:10 pm GMT+10 · Disclaimer
About The Author
